Weeks af­ter start­ing, Am­gen flash­es yel­low light on PhI­II of $400M eczema bet

Am­gen is tak­ing its foot off the ped­al just a few weeks af­ter be­gin­ning a late-stage tri­al of a Ky­owa Kirin drug for which it dished out $400 mil­lion last year in ex­change for ex-Japan rights.

The Cal­i­for­nia phar­ma has paused the Phase III ROCK­ET-IG­NITE study, ac­cord­ing to its Japan­ese part­ner’s lat­est earn­ings re­port Thurs­day. The 52-week, 570-pa­tient tri­al be­gan in June and is ex­pect­ed to col­lect fi­nal pri­ma­ry out­come da­ta in March 2024, ac­cord­ing to a fed­er­al tri­als data­base, which cites the study as ac­tive, but not re­cruit­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER